查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096452

經導管栓塞和閉塞裝置：市場洞察、競爭格局和市場預測 - 2034 年

Transcatheter Embolization and Occlusion Devices - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

經導管栓塞及閉塞裝置市場概述

概述：

  • 經導管栓塞和閉塞裝置市場預計在 2025 年達到 56.2 億美元，預計到 2034 年將達到 125.5 億美元。這一成長是由全球癌症負擔加重和介入腫瘤學的擴張、血管畸形和周邊血管疾病患病率上升以及先進成像技術和人工智慧輔助導航在栓塞手術中日益普及所驅動的。
  • 全球經導管栓塞和閉塞裝置市場預計在 2026 年至 2034 年的預測期內將以 9.3% 的複合年成長率成長。
  • 按類型分類，預計到 2025 年，非螺旋式器械細分市場將佔 51% 的佔有率，引領經導管栓塞和閉塞器械市場。
  • 按應用領域分類，預計到 2025 年，腫瘤領域將佔市場佔有率的 45%，從而推動經導管栓塞和閉塞裝置市場的發展。
  • 就最終用戶而言，「醫院和診所」細分市場預計到 2025 年將佔 58% 的市場佔有率，引領經導管栓塞和閉塞裝置市場。
  • 預計到 2025 年，北美將以 39% 的銷售額引領全球經導管栓塞和閉塞裝置市場，在全球區域市場佔有率中佔最高地位。

經導管栓塞和閉塞裝置是微創介入器械，包括彈簧圈、血管栓塞器、栓塞顆粒和液體栓塞劑，透過導管輸送，用於阻斷或減少目標血管的血流。介入醫師在即時螢光或斷層成像的引導下，將輸送系統推進至目標血管並注入栓塞劑，從而實現可控且精確的閉塞。這些裝置是現代介入放射學和心臟病學的核心，可用於治療出血、動脈瘤、動靜脈畸形、子宮肌瘤和結構性心臟疾病，並在介入性腫瘤學手術中發揮至關重要的作用，例如經導管動脈化療栓塞術（TACE）和用於治療肝臟、腎臟和肺部腫瘤的放射性栓塞術。市場按類型可分為螺旋式裝置（包括推入式和可脫卸式螺旋彈簧圈）和非螺旋式裝置（包括血流導引裝置、栓塞顆粒、液體栓塞劑和其他栓塞材料）。此外，應用領域涵蓋周邊血管疾病、腫瘤學、神經病學和泌尿系統，而終端用戶主要為醫院和診所。在癌症發生率上升、微創治療結構性轉變以及栓塞材料和輸送系統不斷創新的推動下，經導管栓塞和閉塞裝置已成為介入放射學、腫瘤學和血管醫學中不可或缺的工具。

經導管栓塞和閉塞裝置市場的主要市場促進因素

  • 隨著全球癌症負擔（特別是肝癌、肺癌、腎癌和胰腺癌）的加重，對腫瘤介入治療（如經導管動脈化療栓塞術和放射性栓塞術）的需求不斷成長，預計到 2045 年，全球癌症診斷數量將達到約 3250 萬例。
  • 隨著血管畸形、動脈瘤、動靜脈畸形以及胃腸道和肺出血的日益普遍，需要使用導管進行精確血管閉塞的患者群體正在擴大。
  • 為了減少手術創傷、縮短住院時間和加速患者康復，從開放性手術到微創手術的結構性轉變正在進行中，這加速了栓塞和閉塞裝置在醫院和專科診所的引入。
  • 即時螢光、 3D影像和 AI 輔助導管引導等先進影像和導航技術的整合，提高了手術的準確性和安全性，促進了其在臨床環境中的更廣泛應用。
  • 持續的產品創新，包括生物可吸收和藥物釋放型栓塞材料、下一代可脫卸線圈系統和微導管相容血管栓塞器，正在擴大臨床應用範圍並改善治療效果。
  • 大規模策略併購正在重塑競爭格局。值得關注的例子包括波士頓科學公司於2026年1月宣布以約145億美元收購Penumbra，以及史賽克公司於2025年以49億美元收購Inari Medical，這兩筆交易都將擴大栓塞和血栓切除術的產品系列。
  • 隨著法規核准的不斷擴大，包括下一代線圈、栓塞器和液體栓塞系統獲得 CE 標誌和 FDA 批准，以及新產品的推出，臨床應用在主要市場穩步推進。

推動經導管栓塞和閉塞裝置市場成長的因素

市場促進因素

全球癌症負擔日益加重以及介入性腫瘤學的擴展

經導管栓塞和閉塞裝置市場最重要的促進因素是全球癌症負擔的日益加重以及介入腫瘤學在癌症治療中作用的不斷擴大。經導管局部治療，例如經導管動脈化療栓塞術和放射性栓塞術，在肝癌、肺癌、腎癌和胰腺癌的治療中日益普及。這些療法使臨床醫生能夠將藥物直接輸送到腫瘤，同時阻斷其血液供應，從而最大限度地提高局部治療效果，同時最大限度地降低全身毒性。全球癌症發生率持續上升，預計2045年，全球將有約3,250萬人被診斷出罹患癌症。此外，傳統的外科治療常受到腫瘤位置、病患合併症或疾病分期等因素的限制。隨著腫瘤中心和醫院不斷增加對介入放射學基礎設施的投資，預計到2034年，用於腫瘤手術的栓塞和閉塞裝置的需求將穩定成長。

血管畸形和周圍血管疾病的盛行率增加

隨著血管畸形、動脈瘤、動靜脈畸形和周邊血管疾病發生率的增加，需要精準導管栓塞治療的患者群體也不斷擴大。經導管栓塞和閉塞裝置為控制出血、異常血管連接和血管結構缺陷提供了一種微創且標靶性強的治療方法，從而減少了對開放性手術的依賴。隨著影像技術的進步提高了對這些疾病的檢測準確性，以及醫生對微創治療認知的提高，用於周邊血管介入治療的栓塞彈簧圈、栓塞器和液體栓塞劑的需求持續成長。

市場限制因素

儘管基礎需求強勁，經導管栓塞和閉塞器械市場仍面臨諸多限制因素。手術併發症風險，例如感染疾病、血管損傷或意外的靶外栓塞，可能導致恢復期延長和需要額外干預，在某些情況下會削弱醫生和患者的信心。這些微創手術的成功和安全性很大程度上取決於操作者的專業技能，而某些地區高技能介入放射科醫生和循環系統的短缺限制了手術數量和市場擴張。醫療設備的高成本阻礙了價格敏感型市場和新興市場的普及，而關鍵地區不斷變化的監管要求可能會延長產品核准時間。美國對進口醫療設備組件徵收的關稅進一步推高了製造成本，迫使一些製造商重新考慮其採購和生產策略。此外，不同地區對新型栓塞技術的保險報銷政策也存在差異。儘管疾病負擔不斷加重和向微創醫療轉變等潛在促進因素持續存在，但臨床、人力、成本和監管方面的障礙加在一起，正在減緩成長速度。

區域說明

北美洲

到2025年，北美將佔全球市場銷售額的39%。美國憑藉其介入放射學基礎設施、高癌症和慢性呼吸系統疾病發生率以及清晰的FDA監管流程，在市場上佔主導地位。主要醫療設備製造商的存在和健全的保險報銷體系進一步鞏固了其主導地位。

歐洲

歐洲是一個規模龐大且高度發達的區域市場，這得益於癌症、血管畸形和子宮肌瘤發病率的上升、介入放射學能力的不斷增強以及醫療基礎設施的不斷完善。德國、法國和英國預計將成為區域成長的主要驅動力，這得益於其先進的醫療體系、較高的患者健康意識以及微創介入治療的日益普及。

亞太地區

亞太地區是成長最快的地區，這主要得益於癌症發生率的上升、介入放射學基礎設施的快速擴張，以及中國、日本、印度、韓國和澳洲等國醫療保健投資的增加。預計日本將實現最高成長，這得益於意識提升和先進的診斷能力。

世界其他地區

包括中東、非洲和南美洲在內的「偏遠地區」是一個新興的成長前沿。不斷擴大的醫療基礎設施、日益​​加重的癌症和血管疾病負擔，以及逐步與國際標準接軌的法規結構，正在推動全部區域經導管栓塞和閉塞裝置的普及。

經導管栓塞和閉塞裝置市場的最新發展趨勢

2026年1月，波士頓科學公司宣布達成最終協議，將以約145億美元的現金和股票收購Penumbra公司。該交易預計將於2026年完成。戰略意義：這將使波士頓科學公司能夠大規模進軍機械取栓和神經血管栓塞領域，大大擴展其周邊血管和神經栓塞產品組合。

2026年1月，波士頓科學公司（Boston Scientific）的Embold可移除彈簧圈系統獲得CE認證。此系統是新一代完全可回縮的栓塞彈簧圈，適用於阻斷或減少周邊血管的血流。策略意義：增強波士頓科學公司在歐洲市場的彈簧圈產品組合。

常見問題：

Q1. 經導管栓塞和閉塞裝置市場的成長率是多少？

預計從 2026 年到 2034 年的預測期內，經導管栓塞和閉塞裝置市場將以 9.3% 的複合年成長率成長。

Q2. 經導管栓塞和閉塞裝置市場的市場規模有多大？

經導管栓塞和閉塞裝置市場預計在 2025 年達到 56.2 億美元，預計到 2034 年將達到 125.5 億美元。

Q3. 哪個地區在經導管栓塞和閉塞器械市場中處於主導？

由於高癌症和慢性呼吸系統疾病發生率、健全的FDA法規結構以及主要醫療設備製造商的存在，預計北美主導經導管栓塞和閉塞裝置市場，到2025年將佔全球銷售額的39%。亞太地區預計將成為預測期內成長最快的地區。

第四季：經導管栓塞和閉塞裝置市場的主要促進因素是什麼？

主要促進因素包括全球癌症負擔日益加重以及介入性腫瘤學的擴展。預計到2045年，癌症患者人數將達到約3,250萬人。其他促成因素包括血管畸形和周圍血管疾病盛行率的上升、微創手術日益受到青睞、先進影像技術和人工智慧輔助導航的整合，以及栓塞材料和輸送系統的持續產品創新。

Q5. 經導管栓塞和閉塞裝置市場的主要參與者有哪些公司？

主要公司包括波士頓科學公司、美敦力公司、Penumbra公司、庫克公司、愛德華生命科學公司、Merit醫療系統公司、強生服務公司、樂普醫療科技（北京）有限公司、Kaneka Medix公司和史賽克公司。

目錄

第1章：經導管栓塞與封堵器材市場​​報告簡介

  • 調查範圍
  • 市場區隔
  • 市場假設

第2章：經導管栓塞及封堵器材市場​​摘要整理

  • 市場概覽

第3章：經導管栓塞及封堵器材市場​​關鍵因素分析

  • 經導管栓塞及閉塞裝置市場：市場促進因素
    • 癌症和介入腫瘤學的全球負擔日益加重
    • 血管畸形和周圍血管疾病（PVD）盛行率增加
    • 人們越來越傾向微創手術
    • 先進的影像診斷、導航和人工智慧輔助引導
  • 經導管栓塞和閉塞裝置市場的市場限制和挑戰。
    • 該手術可能出現的併發症以及對執業者的技能要求。
    • 高成本且報銷金額波動較大
    • 與監管和關稅相關的成本壓力
  • 經導管栓塞及閉塞裝置市場：市場機會
    • 生物可吸收及藥物釋放型栓塞材料
    • 新興市場和人工智慧技術的擴張

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：經導管栓塞與封堵器材市場​​的波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的競爭

第7章：經導管栓塞及閉塞裝置市場評估

  • 按類型
    • 線圈
    • 非線圈
  • 用途別
    • 周邊血管疾病
    • 腫瘤學
    • 神經病學
    • 泌尿系統
    • 其他
  • 最終用戶
    • 醫院和診所
    • 門診手術中心
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：經導管栓塞與封堵器材市場​​的競爭格局

  • 市場集中度與結構
  • 競爭定位與市場佔有率分析（加值服務）

第9章：經導管栓塞和封堵器材市場​​的新創企業資金籌措和投資趨勢

第10章：經導管栓塞和封堵器材市場​​：公司概況和產品概況

  • Boston Scientific Corporation
    • 公司簡介
    • 公司簡介
    • 財務概覽
    • 服務組合
    • 策略舉措/熵
  • Medtronic
    • 產品系列
  • Penumbra, Inc.
  • Cook
  • Edwards Lifesciences Corporation
  • Merit Medical Systems, Inc.
  • Johnson & Johnson Services, Inc.
  • Lepu Medical Technology(Beijing) Co., Ltd
  • Kaneka Medix Corporation
  • Stryker

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0074

Transcatheter Embolization and Occlusion Devices Market Summary

Overview:

  • The transcatheter embolization and occlusion devices market is estimated at USD 5.62 billion in 2025 and is projected to reach USD 12.55 billion by 2034. Growth is anchored in the rising global burden of cancer and expanding interventional oncology, the growing prevalence of vascular malformations and peripheral vascular disease, and the increasing integration of advanced imaging and AI-assisted navigation into embolization procedures.
  • The global Transcatheter Embolization and Occlusion Devices market is growing at a CAGR of 9.3% during the forecast period from 2026 to 2034.
  • By type, the Non-Coiled devices segment dominated the Transcatheter Embolization and Occlusion Devices market with a 51% share in 2025.
  • By application, the Oncology segment dominated the Transcatheter Embolization and Occlusion Devices market with a 45% share in 2025.
  • By end-users, the Hospitals & Clinics segment dominated the Transcatheter Embolization and Occlusion Devices market with a 58% share in 2025.
  • North America dominated the global Transcatheter Embolization and Occlusion Devices market revenue with a 39% share in 2025, representing the highest regional market share globally.

Transcatheter embolization and occlusion devices are minimally invasive interventional tools, including coils, vascular plugs, embolization particles, and liquid embolic agents, that are deployed through a catheter to intentionally block or reduce blood flow within a targeted blood vessel. Guided by real-time fluoroscopic or cross-sectional imaging, an interventionalist advances a delivery system to the target vessel and introduces an embolic agent to achieve controlled, precise occlusion. These devices are central to modern interventional radiology and cardiology, supporting the management of hemorrhage, aneurysms, arteriovenous malformations, uterine fibroids, and structural heart defects, and are integral to interventional oncology procedures such as transcatheter arterial chemoembolization (TACE) and radioembolization for liver, kidney, and lung tumors. The market is organized by type across coiled devices, including pushable and detachable coils, and non-coiled devices, including flow-diverting devices, embolization particles, liquid embolic agents, and other embolic materials; by application, spanning peripheral vascular disease, oncology, neurology, and urology; and by end-user, led by hospitals and clinics. Driven by rising cancer prevalence, a structural shift toward minimally invasive care, and continuous innovation in embolic materials and delivery systems, transcatheter embolization and occlusion devices have become indispensable tools across interventional radiology, oncology, and vascular medicine.

Transcatheter Embolization and Occlusion Devices Market Key Growth Drivers

  • The rising global burden of cancer, particularly liver, lung, kidney, and pancreatic cancers, is expanding demand for interventional oncology procedures such as TACE and radioembolization, with cancer diagnoses projected to reach approximately 32.5 million globally by 2045.
  • The growing prevalence of vascular malformations, aneurysms, arteriovenous malformations, and gastrointestinal and pulmonary hemorrhage is expanding the addressable pool of patients requiring precise, catheter-based vascular occlusion.
  • A structural shift toward minimally invasive procedures over open surgery, driven by reduced surgical trauma, shorter hospital stays, and faster patient recovery, is accelerating adoption of embolization and occlusion devices across hospitals and specialized clinics.
  • Integration of advanced imaging and navigation, including real-time fluoroscopy, three-dimensional imaging, and AI-assisted catheter guidance, is improving procedural precision and safety, encouraging wider clinical adoption.
  • Continuous product innovation, including bioresorbable and drug-eluting embolic materials, next-generation detachable coil systems, and microcatheter-compatible vascular plugs, is broadening clinical applications and improving procedural outcomes.
  • Large-scale strategic consolidation is reshaping the competitive landscape, headlined by Boston Scientific's agreement to acquire Penumbra for approximately USD 14.5 billion, announced in January 2026, and Stryker's USD 4.9 billion acquisition of Inari Medical in 2025, both expanding embolization and thrombectomy portfolios.
  • Expanding regulatory approvals and new product launches, including CE Mark and FDA clearances for next-generation coils, plugs, and liquid embolic systems, are sustaining a steady cadence of clinical adoption across major markets.

Key Companies in Transcatheter Embolization and Occlusion Devices Market

The competitive landscape is led by the following active device manufacturers:

  • Boston Scientific Corporation
  • Medtronic
  • Penumbra, Inc.
  • Cook
  • Edwards Lifesciences Corporation
  • Merit Medical Systems, Inc.
  • Johnson & Johnson Services, Inc.
  • Lepu Medical Technology(Beijing) Co., Ltd
  • Kaneka Medix Corporation
  • Stryker

Factors Contributing to the Growth of the Transcatheter Embolization and Occlusion Devices Market

Market Drivers

Rising Global Cancer Burden and Expanding Interventional Oncology

The most significant driver of the Transcatheter Embolization and Occlusion Devices market is the rising global burden of cancer and the expanding role of interventional oncology in its management. Liver, lung, kidney, and pancreatic cancers are increasingly managed through catheter-based, localized therapies such as transcatheter arterial chemoembolization and radioembolization, which enable clinicians to deliver therapeutic agents directly to a tumor while simultaneously occluding its blood supply, maximizing local efficacy while minimizing systemic toxicity. Cancer incidence continues to rise globally, with projections indicating that approximately 32.5 million individuals worldwide will be diagnosed with cancer by 2045, and conventional surgical options are often limited by tumor location, patient comorbidities, or advanced disease stage. As oncology centers and hospitals continue to invest in interventional radiology infrastructure, demand for embolization and occlusion devices used in oncological procedures is expected to expand steadily through 2034.

Growing Prevalence of Vascular Malformations and Peripheral Vascular Disease

The increasing incidence of vascular malformations, aneurysms, arteriovenous malformations, and peripheral vascular disease is expanding the patient population requiring precise, catheter-based vascular occlusion. Transcatheter embolization and occlusion devices provide a minimally invasive, targeted approach to managing uncontrolled bleeding, abnormal vessel connections, and structural vascular defects, reducing reliance on open surgical repair. As diagnostic imaging improves detection of these conditions and physician awareness of minimally invasive treatment options grows, demand for embolization coils, plugs, and liquid embolic agents used in peripheral vascular interventions continues to rise.

Market Restraints

Despite strong underlying demand, the Transcatheter Embolization and Occlusion Devices market faces material constraints. The risk of procedural complications, including infection, vessel injury, or inadvertent non-target embolization, can lead to extended recovery times or the need for additional interventions, tempering physician and patient confidence in certain settings. The success and safety of these minimally invasive procedures depend heavily on operator expertise, and a shortage of highly skilled interventional radiologists and cardiologists in some regions constrains procedural volumes and market expansion. High device costs limit adoption in price-sensitive and emerging markets, while evolving regulatory requirements across major geographies can lengthen product approval timelines. U.S. tariffs on imported medical device components have further increased manufacturing costs, prompting some manufacturers to reconsider sourcing and production strategies. Reimbursement policy for newer embolic technologies also remains uneven across geographies. Together, these clinical, workforce, cost, and regulatory barriers temper the pace of growth, even as the underlying drivers of rising disease burden and the shift toward minimally invasive care remain firmly intact.

Transcatheter Embolization and Occlusion Devices Market Segment Analysis

The Transcatheter Embolization and Occlusion Devices by Type (Coiled [Pushable Coils, Detachable Coils], Non-Coiled [Flow Diverting Devices, Embolization Particles, Liquid Embolic, Others]), Application (Peripheral Vascular Disease, Oncology, Neurology, Urology, Others), End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of World).

By Type

Dominant Subsegment: Non-Coiled Devices. The non-coiled devices category is expected to dominate the market.

Dominant: Small Molecule ~ 51%

The non-coiled segment accounted for 51% of the transcatheter embolization and occlusion devices market in 2025. Non-coiled devices, including flow-diverting devices, embolization particles, and liquid embolic agents, are the leading type because they offer precise vascular occlusion with predictable deployment, making them particularly effective for treating larger vessels, high-flow vascular malformations, and complex tumors. Unlike traditional coils, non-coiled devices such as vascular plugs and drug-eluting microspheres provide controlled delivery of embolic material with a reduced risk of migration and are especially preferred in procedures such as transcatheter arterial chemoembolization, uterine artery embolization, and management of gastrointestinal or pulmonary hemorrhage. Continued innovation, including bioresorbable plugs and drug-eluting microspheres, is further enhancing therapeutic efficacy. While coiled devices, particularly detachable coils, remain essential for neurovascular and aneurysm applications, the versatility and expanding procedural use of non-coiled devices secure the segment's leadership across the forecast period.

By Application

Dominant Subsegment: Oncology. The oncology category is expected to dominate the market.

Dominant: Oncology ~ 45%

The oncology segment accounted for 45% of the Transcatheter Embolization and Occlusion Devices market in 2025. Oncology is the leading application because embolization devices are integral to procedures such as transcatheter arterial chemoembolization and radioembolization, which are widely used to treat primary and metastatic liver, lung, kidney, and pancreatic tumors. These procedures enable the precise delivery of therapeutic agents directly to the tumor site while simultaneously occluding its blood supply, maximizing local efficacy while limiting systemic toxicity, particularly valuable for patients whose tumor location, comorbidities, or disease stage limit surgical options. Embolization and occlusion devices also play a critical role in managing cancer-related complications such as tumor hemorrhage. As oncology centers and hospitals continue to invest in advanced interventional radiology infrastructure and newer embolic materials, including drug-eluting beads and bioresorbable agents, the oncology segment is expected to retain its leadership through 2034.

Transcatheter Embolization and Occlusion Devices Market Region Analysis

Dominant Region: North America

Dominant: North America ~ 39% (Largest)

North America accounted for 39% of the global transcatheter embolization and occlusion devices market revenue in 2025, representing the highest regional market share globally. The region's dominance is driven by the high prevalence of cancer and chronic respiratory disorders, including COPD, in the United States, along with associated risk factors that increase demand for embolization procedures such as bronchial artery embolization and transcatheter arterial chemoembolization. The widespread adoption of advanced medical technologies, robust FDA regulatory frameworks, and a dense network of interventional radiology centers reinforce the region's leadership. Cancer prevalence continues to rise sharply in the United States, and the presence of leading device manufacturers, including Boston Scientific, Medtronic, Penumbra, and Merit Medical, alongside strong reimbursement and a deep clinical evidence base, sustains substantial procedural volumes and device demand across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the transcatheter embolization and occlusion devices market, reflecting a robust CAGR of approximately 10.8% during the forecast period. The region's elevated growth is driven by the rising prevalence of cancer, particularly liver and lung cancers, expanding healthcare investment, and rapid growth in interventional radiology infrastructure across China, Japan, India, South Korea, and Australia. Technological advancements in device design and procedural technique are enhancing the safety and effectiveness of embolization procedures, building confidence among healthcare providers and patients across the region. Japan is expected to experience particularly strong growth, supported by advanced diagnostic capabilities and a strong clinical focus on outcomes and cost-effectiveness, positioning Asia-Pacific as the principal source of incremental growth in the global market through 2034.

Regional Commentary

North America

North America accounted for 39% of the global market revenue in 2025. The United States dominates on the strength of its interventional radiology infrastructure, high cancer and chronic respiratory disease burden, and clear FDA regulatory pathways, while the presence of leading device manufacturers and strong reimbursement frameworks reinforce its leadership.

Europe

Europe is a large and advanced regional market, supported by the rising prevalence of cancer, vascular malformations, and uterine fibroids, expanding interventional radiology capabilities, and improving healthcare infrastructure. Germany, France, and the United Kingdom are expected to lead regional growth, supported by advanced healthcare systems, high patient awareness, and increasing adoption of minimally invasive interventions.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising cancer incidence, rapid expansion of interventional radiology infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Japan is expected to experience the highest growth, supported by improved patient awareness and advanced diagnostic capabilities.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. Expanding healthcare infrastructure, rising cancer and vascular disease burden, and gradual alignment of regulatory frameworks with global standards are broadening access to transcatheter embolization and occlusion devices across the region.

Transcatheter Embolization and Occlusion Devices Market Competitive Landscape

The Transcatheter Embolization and Occlusion Devices market is classified as Moderately Consolidated. A group of scaled, multinational players including Boston Scientific, Medtronic, Stryker, and Terumo anchor the top tier through broad product portfolios spanning coiled and non-coiled devices, while specialized providers such as Penumbra, Merit Medical, Cook, and Edwards Lifesciences compete through focused innovation in vascular plugs, embolization particles, and structural occlusion technologies. Large-scale consolidation, most notably Boston Scientific's pending acquisition of Penumbra, is expected to further concentrate competitive scale among the market's leading players.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Moderately consolidated, with a small group of scaled multinational manufacturers leading and specialized providers competing on focused innovation.
  • Leading players: Boston Scientific, Medtronic, Stryker, and Terumo anchor the top tier through broad, multi-category embolization and occlusion portfolios.
  • Product portfolio strength: Top players offer end-to-end portfolios spanning pushable and detachable coils, vascular plugs, embolization particles, and liquid embolic systems.
  • M&A activity: Active consolidation, including Boston Scientific's approximately USD 14.5 billion agreement to acquire Penumbra (January 2026) and Stryker's USD 4.9 billion acquisition of Inari Medical (2025).
  • Innovation focus: Bioresorbable and drug-eluting embolic materials, extended-length detachable coil systems, microcatheter-compatible vascular plugs, and AI-assisted procedural planning.
  • Regulatory strength: A steady cadence of FDA clearances, premarket approvals, and CE Mark approvals for next-generation coils, plugs, and liquid embolic systems underpins competitive positioning.
  • Manufacturing capabilities: Nitinol and polymer-based device engineering, sterile packaging, and global distribution networks are key competitive moats.
  • Geographic reach: Leaders operate global commercial and manufacturing networks, supporting broad distribution across North America, Europe, and Asia-Pacific.

Transcatheter Embolization and Occlusion Devices Market Recent Developmental Activities

In January 2026, Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc. for approximately USD 14.5 billion in cash and stock, a deal expected to close in 2026. Strategic significance: Provides scaled entry into mechanical thrombectomy and neurovascular embolization and substantially expands Boston Scientific's peripheral and neuro embolization portfolio.

In January 2026, Boston Scientific Corporation received CE Mark approval for its Embold detachable coil system, a new generation of fully retractable embolization coils indicated to obstruct or reduce blood flow in the peripheral vasculature. Strategic significance: Strengthens Boston Scientific's coiled-device portfolio in the European market.

Transcatheter Embolization and Occlusion Devices Market Segmentation

Transcatheter Embolization and Occlusion Devices Market by Type

  • Coiled
  • Pushable Coils
  • Detachable Coils
  • Non-Coiled
  • Flow Diverting Devices
  • Embolization Particles
  • Liquid Embolic
  • Others

Transcatheter Embolization and Occlusion Devices Market by Application

  • Peripheral Vascular Disease
  • Oncology
  • Neurology
  • Urology
  • Others

Transcatheter Embolization and Occlusion Devices Market by End-Users

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Transcatheter Embolization and Occlusion Devices Market by Geography

  • North America Transcatheter Embolization and Occlusion Devices Market
  • United States Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Canada Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Mexico Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Europe Transcatheter Embolization and Occlusion Devices Market
  • Germany Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • United Kingdom Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • France Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Italy Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Spain Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Rest of Europe Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Asia-Pacific Transcatheter Embolization and Occlusion Devices Market
  • China Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Japan Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • India Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Australia Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • South Korea Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Transcatheter Embolization and Occlusion Devices Market
  • Middle East Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • Africa Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
  • South America Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)

Key Takeaways from the Transcatheter Embolization and Occlusion Devices Market Report Study

  • Market size analysis for the current transcatheter embolization and occlusion devices market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global transcatheter embolization and occlusion devices market.
  • Various opportunities available for competitors in the transcatheter embolization and occlusion devices market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current Transcatheter embolization and occlusion devices market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for transcatheter embolization and occlusion devices market growth in the future?

Target audience who can benefit from this Transcatheter Embolization and Occlusion Devices market report study

  • Transcatheter embolization and occlusion devices product providers
  • Research organizations and consulting companies
  • Transcatheter embolization and occlusion devices-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in transcatheter embolization and occlusion devices
  • Various end-users who want to know more about the transcatheter embolization and occlusion devices market and the latest technological developments in the transcatheter embolization and occlusion devices market.

Frequently Asked Questions:

Q1. What is the growth rate of the transcatheter embolization and occlusion devices market?

The transcatheter embolization and occlusion devices market is projected to expand at a CAGR of 9.3% during the forecast period from 2026-2034.

Q2. What is the market size of the transcatheter embolization and occlusion devices market?

The Transcatheter Embolization and Occlusion Devices market is estimated at USD 5.62 billion in 2025 and is projected to reach USD 12.55 billion by 2034.

Q3. Which region dominates the transcatheter embolization and occlusion devices market?

North America dominated the Transcatheter Embolization and Occlusion Devices market with a 39% share of global revenue in 2025, supported by high cancer and chronic respiratory disease prevalence, robust FDA regulatory frameworks, and the presence of leading device manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the transcatheter embolization and occlusion devices market?

The principal drivers are the rising global burden of cancer and expansion of interventional oncology, with cancer cases projected to reach approximately 32.5 million by 2045; the growing prevalence of vascular malformations and peripheral vascular disease; the increasing preference for minimally invasive procedures; integration of advanced imaging and AI-assisted navigation; and continued product innovation in embolic materials and delivery systems.

Q5. Who are the major players in the transcatheter embolization and occlusion devices market?

The major players include Boston Scientific Corporation, Medtronic, Penumbra, Inc., Cook, Edwards Lifesciences Corporation, Merit Medical Systems, Inc., Johnson & Johnson Services, Inc., Lepu Medical Technology(Beijing) Co., Ltd, Kaneka Medix Corporation, Stryker, among others.

Table of Contents

1. Transcatheter Embolization and Occlusion Devices Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Transcatheter Embolization and Occlusion Devices Market Executive Summary

  • 2.1 Market at a Glance

3. Transcatheter Embolization and Occlusion Devices Market Key Factors Analysis

  • 3.1 Transcatheter Embolization and Occlusion Devices Market Drivers
    • 3.1.1 Rising Global Cancer Burden and Interventional Oncology
    • 3.1.2 Growing Prevalence of Vascular Malformations and PVD
    • 3.1.3 Increasing Preference for Minimally Invasive Procedures
    • 3.1.4 Advanced Imaging, Navigation, and AI-Assisted Guidance
  • 3.2 Transcatheter Embolization and Occlusion Devices Market Restraints and Challenges
    • 3.2.1 Procedural Complications and Operator Skill Requirements
    • 3.2.2 High Device Costs and Reimbursement Variability
    • 3.2.3 Regulatory and Tariff-Related Cost Pressures
  • 3.3 Transcatheter Embolization and Occlusion Devices Market Opportunities
    • 3.3.1 Bioresorbable and Drug-Eluting Embolic Materials
    • 3.3.2 Emerging-Market and AI-Enabled Procedural Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Transcatheter Embolization and Occlusion Devices Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Transcatheter Embolization and Occlusion Devices Market Assessment

  • 7.1 By Type
    • 7.1.1 Coiled
      • 7.1.1.1 Pushable Coils
      • 7.1.1.2 Detachable Coils
    • 7.1.2 Non-Coiled
      • 7.1.2.1 Flow Diverting Devices
      • 7.1.2.2 Embolization Particles
      • 7.1.2.3 Liquid Embolic
      • 7.1.2.4 Others
  • 7.2 By Application
    • 7.2.1 Peripheral Vascular Disease
    • 7.2.2 Oncology
    • 7.2.3 Neurology
    • 7.2.4 Urology
    • 7.2.5 Others
  • 7.3 By End-Users
    • 7.3.1 Hospitals & Clinics
    • 7.3.2 Ambulatory Surgical Centers
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.1.2 Canada Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.1.3 Mexico Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
    • 7.4.2 Europe
      • 7.4.2.1 Germany Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.2.2 United Kingdom Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.2.3 France Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.2.4 Italy Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.2.5 Spain Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.2.6 Rest of Europe Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.3.2 Japan Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.3.3 India Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.3.4 Australia Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.3.5 South Korea Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.3.6 Rest of Asia-Pacific Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
    • 7.4.4 Rest of World
      • 7.4.4.1 Middle East Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.4.2 Africa Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)
      • 7.4.4.3 South America Transcatheter Embolization and Occlusion Devices Market Size in USD million (2023-2034)

8. Transcatheter Embolization and Occlusion Devices Market Competitive Landscape

  • 8.1 Market Concentration and Structure
  • 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Transcatheter Embolization and Occlusion Devices Market Startup Funding and Investment Trends

10. Transcatheter Embolization and Occlusion Devices Market Company and Product Profiles

  • 10.1 Boston Scientific Corporation
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Service Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 Medtronic
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 Penumbra, Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 Cook
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 Edwards Lifesciences Corporation
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 Merit Medical Systems, Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 Johnson & Johnson Services, Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 Lepu Medical Technology(Beijing) Co., Ltd
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Kaneka Medix Corporation
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy
  • 10.10 Stryker
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Transcatheter Embolization and Occlusion Devices Market in Global (2023-2034)
  • Table 2: Transcatheter Embolization and Occlusion Devices Market in Global by Type (2023-2034)
  • Table 3: Transcatheter Embolization and Occlusion Devices Market in Global by Application (2023-2034)
  • Table 4: Transcatheter Embolization and Occlusion Devices Market in Global by End-Users (2023-2034)
  • Table 5: Transcatheter Embolization and Occlusion Devices Market in Global by Geography (2023-2034)
  • Table 6: Transcatheter Embolization and Occlusion Devices Market in North America (2023-2034)
  • Table 7: Transcatheter Embolization and Occlusion Devices Market in the United States (2023-2034)
  • Table 8: Transcatheter Embolization and Occlusion Devices Market in Canada (2023-2034)
  • Table 9: Transcatheter Embolization and Occlusion Devices Market in Mexico (2023-2034)
  • Table 10: Transcatheter Embolization and Occlusion Devices Market in Europe (2023-2034)
  • Table 11: Transcatheter Embolization and Occlusion Devices Market in Germany (2023-2034)
  • Table 12: Transcatheter Embolization and Occlusion Devices Market in United Kingdom (2023-2034)
  • Table 13: Transcatheter Embolization and Occlusion Devices Market in France (2023-2034)
  • Table 14: Transcatheter Embolization and Occlusion Devices Market in Italy (2023-2034)
  • Table 15: Transcatheter Embolization and Occlusion Devices Market in Spain (2023-2034)
  • Table 16: Transcatheter Embolization and Occlusion Devices Market in the Rest of Europe (2023-2034)
  • Table 17: Transcatheter Embolization and Occlusion Devices Market in Asia-Pacific (2023-2034)
  • Table 18: Transcatheter Embolization and Occlusion Devices Market in China (2023-2034)
  • Table 19: Transcatheter Embolization and Occlusion Devices Market in Japan (2023-2034)
  • Table 20: Transcatheter Embolization and Occlusion Devices Market in India (2023-2034)
  • Table 21: Transcatheter Embolization and Occlusion Devices Market in Australia (2023-2034)
  • Table 22: Transcatheter Embolization and Occlusion Devices Market in South Korea (2023-2034)
  • Table 23: Transcatheter Embolization and Occlusion Devices Market in Rest of Asia-Pacific (2023-2034)
  • Table 24: Transcatheter Embolization and Occlusion Devices Market in the Rest of the World (2023-2034)
  • Table 25: Transcatheter Embolization and Occlusion Devices Market in the Middle East (2023-2034)
  • Table 26: Transcatheter Embolization and Occlusion Devices Market in Africa (2023-2034)
  • Table 27: Transcatheter Embolization and Occlusion Devices Market in South America (2023-2034)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Transcatheter Embolization and Occlusion Devices Market Drivers
  • Figure 2: Transcatheter Embolization and Occlusion Devices Market Restraints
  • Figure 3: Transcatheter Embolization and Occlusion Devices Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Transcatheter Embolization and Occlusion Devices Market in Global (2023-2034)
  • Figure 9: Transcatheter Embolization and Occlusion Devices Market in Global by Type (2023-2034)
  • Figure 10: Transcatheter Embolization and Occlusion Devices Market in Global by Application (2023-2034)
  • Figure 11: Transcatheter Embolization and Occlusion Devices Market in Global by End-Users (2023-2034)
  • Figure 12: Transcatheter Embolization and Occlusion Devices Market in Global by Geography (2023-2034)
  • Figure 13: Transcatheter Embolization and Occlusion Devices Market in North America (2023-2034)
  • Figure 14: Transcatheter Embolization and Occlusion Devices Market in the United States (2023-2034)
  • Figure 15: Transcatheter Embolization and Occlusion Devices Market in Canada (2023-2034)
  • Figure 16: Transcatheter Embolization and Occlusion Devices Market in Mexico (2023-2034)
  • Figure 17: Transcatheter Embolization and Occlusion Devices Market in Europe (2023-2034)
  • Figure 18: Transcatheter Embolization and Occlusion Devices Market in Germany (2023-2034)
  • Figure 19: Transcatheter Embolization and Occlusion Devices Market in United Kingdom (2023-2034)
  • Figure 20: Transcatheter Embolization and Occlusion Devices Market in France (2023-2034)
  • Figure 21: Transcatheter Embolization and Occlusion Devices Market in Italy (2023-2034)
  • Figure 22: Transcatheter Embolization and Occlusion Devices Market in Spain (2023-2034)
  • Figure 23: Transcatheter Embolization and Occlusion Devices Market in the Rest of Europe (2023-2034)
  • Figure 24: Transcatheter Embolization and Occlusion Devices Market in Asia-Pacific (2023-2034)
  • Figure 25: Transcatheter Embolization and Occlusion Devices Market in China (2023-2034)
  • Figure 26: Transcatheter Embolization and Occlusion Devices Market in Japan (2023-2034)
  • Figure 27: Transcatheter Embolization and Occlusion Devices Market in India (2023-2034)
  • Figure 28: Transcatheter Embolization and Occlusion Devices Market in Australia (2023-2034)
  • Figure 29: Transcatheter Embolization and Occlusion Devices Market in South Korea (2023-2034)
  • Figure 30: Transcatheter Embolization and Occlusion Devices Market in Rest of Asia-Pacific (2023-2034)
  • Figure 31: Transcatheter Embolization and Occlusion Devices Market in the Rest of the World (2023-2034)
  • Figure 32: Transcatheter Embolization and Occlusion Devices Market in the Middle East (2023-2034)
  • Figure 33: Transcatheter Embolization and Occlusion Devices Market in Africa (2023-2034)
  • Figure 34: Transcatheter Embolization and Occlusion Devices Market in South America (2023-2034)
  • Figure 35: Competitive Landscape
  • Figure 36: Startup Funding and Investment Trends